Trastuzumab: updated mechanisms of action and resistance in breast cancer

HER2-postitive breast cancer has the second-poorest prognosis among breast cancer subtypes. One of the most effective targeted therapies for patients with HER2-positive breast cancer is trastuzumab-based. However, primary or acquired resistance to trastuzumab has been a major obstacle in the clinica...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Francois X. Claret, Thuy T Vu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2012-06-01
Seri Bilgileri:Frontiers in Oncology
Konular:
breast cancer
targeted therapies
HER2/ERBB2
HER3
Herceptin
trastuzumab
Online Erişim:http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00062/full
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller